Table 2.
In vitro susceptibility of 352 bacterial isolates to potential topical ophthalmic antibiotics.
| Antibiotic | Corynebacterium | Escherichia | Othera | Pasteurella sp. | Pseudomonas sp. | Staphylococcus sp. | Streptococcus sp. | Total |
|---|---|---|---|---|---|---|---|---|
| sp. | coli | |||||||
| Amikacin | 96% (26/27) | 90% (9/10) | 78% (49/63) | 88% (15/17) | 93% (41/44) | 98% (120/123) | 16% (11/68) | 77% (271/352) |
| Bacitracin | 48% (13/27) | 0% (0/10) | 11% (7/63) | 0% (0/17) | 2% (1/44) | 0% (0/123) | 3% (2/68) | 7% (23/352) |
| Cefazolin | 11% (3/27) | 0% (0/10) | 13% (8/63) | 12% (2/17) | 0% (0/44) | 7% (9/123) | 9% (6/68) | 8% (28/352) |
| Ceftiofur | 81% (22/27) | 100% (10/10) | 75% (47/63) | 94% (16/17) | 20% (9/44) | 88% (108/123) | 99% (67/68) | 79% (279/352) |
| Chloramphenicol | 93% (25/27) | 100% (10/10) | 87% (55/63) | 94% (16/17) | 20% (9/44) | 88% (108/123) | 100% (68/68) | 83% (291/352) |
| Ciprofloxacin | 78% (21/27) | 100% (10/10) | 56% (35/63) | 29% (5/17) | 95% (42/44) | 79% (97/123) | 47% (32/68) | 69% (242/352) |
| Doxycycline | 96% (26/27) | 90% (9/10) | 48% (30/63) | 94% (16/17) | 27% (12/44) | 54% (66/123) | 35% (24/68) | 52% (183/352) |
| Erythromycin | 67% (18/27) | 0% (0/10) | 13% (8/63) | 47% (8/17) | 0% (0/44) | 59% (72/123) | 1% (1/68) | 30% (107/352) |
| Gentamicin | 89% (24/27) | 100% (10/10) | 83% (52/63) | 94% (16/17) | 98% (43/44) | 72% (89/123) | 41% (28/68) | 74% (262/352) |
| Moxifloxacin | 4% (1/27) | 0% (0/10) | 3% (2/63) | 0% (0/17) | 0% (0/44) | 80% (99/123) | 1% (1/68) | 29% (103/352) |
| Neomycin | 100% (27/27) | 90% (9/10) | 83% (52/63) | 100% (17/17) | 93% (41/44) | 89% (109/123) | 19% (13/68) | 76% (268/352) |
| Neomycin/Polymyxin B/Bacitracin | 100% (27/27) | 90% (9/10) | 83% (52/63) | 100% (17/17) | 93% (41/44) | 89% (109/123) | 22% (15/68) | 77% (270/352) |
| Ofloxacin | 41% (11/27) | 50% (5/10) | 27% (17/63) | 29% (5/17) | 45% (20/44) | 80% (98/123) | 46% (31/68) | 53% (187/352) |
| Oxytetracycline | 85% (23/27) | 80% (8/10) | 78% (49/63) | 100% (17/17) | 41% (18/44) | 54% (66/123) | 63% (43/68) | 64% (224/352) |
| Oxytetracycline/Polymyxin B | 85% (23/27) | 80% (8/10) | 78% (49/63) | 100% (17/17) | 41% (18/44) | 54% (66/123) | 63% (43/68) | 64% (224/352) |
| Polymyxin B | 0% (0/27) | 0% (0/10) | 0% (0/63) | 0% (0/17) | 0% (0/44) | 0% (0/123) | 0% (0/68) | 0% (0/352) |
| Polymyxin B/ Trimethoprim | 89% (24/27) | 90% (9/10) | 44% (28/63) | 12% (2/17) | 18% (8/44) | 74% (91/123) | 18% (12/68) | 49% (174/352) |
| Ticarcillin | 44% (12/27) | 80% (8/10) | 54% (34/63) | 29% (5/17) | 64% (28/44) | 40% (49/123) | 56% (38/68) | 49% (174/352) |
| Tobramycin | 44% (12/27) | 100% (10/10) | 51% (32/63) | 29% (5/17) | 100% (44/44) | 76% (93/123) | 6% (4/68) | 57% (200/352) |
| Trimethoprim/Sulfamethoxazole | 89% (24/27) | 90% (9/10) | 44% (28/63) | 12% (2/17) | 18% (8/44) | 74% (91/123) | 18% (12/68) | 49% (174/352) |
a
Other organisms include Actinomyces sp. (8), Enterococcus sp. (6), Acinetobacter sp. (4), Enterobacter sp. (4), gram(+) organism (non-specified) (4), gram(-) non-fermenter (non-specified) (4), Moraxella sp. (4), Neisseria sp. (4), gram(-) organism (non-specified) (3), Micrococcus sp. (3), Proteus mirabilis (3), Serratia marcescens (3), Bacillus sp. (2), Cutibacterium acnes (2), Klebsiella sp. (2), Achromobacter xylosoxidans (1), Capnocytophaga sp. (1), Cardiobacterium sp. (1), Chryseobacterium sp. (1), Providencia rettgeri (1), Rhodococcus sp. (1), Rothia sp. (1).